Merck, Moderna Melanoma Vaccine Study Succeeds

Now to a potential breakthrough in the fight against skin cancer. Merck and Moderna said their personalized cancer vaccines helped cut the reoccurrence of melanoma in a late in a large late stage trial. Bloomberg's Madison Muller covers the sector and joins us.I don't know where to start, Madison, whether it's the breakthrough or just the huge move in Moderna shares this morning. This is a really big reaction to the study. Totally.I mean, there are we're winning sort of on multiple fronts here, and I think ...